Skip to main content
. Author manuscript; available in PMC: 2009 Oct 5.
Published in final edited form as: Pharmacotherapy. 2008 Sep;28(9):1084–1097. doi: 10.1592/phco.28.9.1084

Figure 1.

Figure 1

Warfarin pharmacokinetic and pharmacodynamics pathway. Warfarin is administered as a racemic admixture of R and S enantiomers. The more potent S enantiomer is metabolized principally by Cytochrome P4502C9 (CYP2C9). The pharmacological effect of warfarin is mediated by the inhibition of Vitamin K epoxide reductase complex 1 (VKORC1). This results in the decreased concentrations of activated clotting factors (II, VII, IX and X) producing therapeutic anticoagulation.